Format

Send to

Choose Destination
Clin J Am Soc Nephrol. 2014 Mar;9(3):617-25. doi: 10.2215/CJN.07260713. Epub 2013 Sep 26.

Glomerular diseases: emerging tests and therapies for IgA nephropathy.

Author information

1
Division of Nephrology, Columbia University College of Physicians and Surgeons, New York, New York.

Abstract

The last decade has seen major progress in understanding the pathogenesis as well as the prognosis and treatment of patients with IgA nephropathy (IgAN). Although the diagnostic criterion of a kidney biopsy demonstrating dominant or codominant IgA deposition remains unchanged, much more is known about the genetic and environmental factors predisposing to disease development and progression. These advances have led to the identification of novel diagnostic and prognostic markers. Among the most promising clinically are genetic profiling, quantification of galactose-deficient IgA1 levels, and measurement of anti-IgA1 immunoglobulins. While targeted treatment for IgAN remains elusive, there is mounting evidence for therapeutic interventions that alter the disease course. The appropriate validation and integration of these discoveries into clinical care represent a major challenge, but one that holds tremendous promise for refining prognostication, guiding therapy, and improving the lives of patients with IgAN.

PMID:
24071652
PMCID:
PMC3944769
DOI:
10.2215/CJN.07260713
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for HighWire Icon for PubMed Central
Loading ...
Support Center